120 results on '"Ma, Leina"'
Search Results
2. Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function
3. UBC9 stabilizes PFKFB3 to promote aerobic glycolysis and proliferation of glioblastoma cells
4. The interplay of the circadian clock and metabolic tumorigenesis
5. Bioinformatics analysis identified RGS4 as a potential tumor promoter in glioma
6. Governing glutaminolysis by regulation of glutaminase succinylation
7. Base editing of the mutated TERT promoter inhibits liver tumor growth
8. Bi-level Planning of Rural Energy System Considering Flexible Loads Coordination
9. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
10. Circular RNA In Invasive and Recurrent Clinical Nonfunctioning Pituitary Adenomas: Expression Profiles and Bioinformatic Analysis
11. The moonlighting function of glycolytic enzyme enolase-1 promotes choline phospholipid metabolism and tumor cell proliferation
12. Supplementary Figure 5 from Overexpression of the Transcription Factor MEF2D in Hepatocellular Carcinoma Sustains Malignant Character by Suppressing G2–M Transition Genes
13. Supplementary Figure 3 from Overexpression of the Transcription Factor MEF2D in Hepatocellular Carcinoma Sustains Malignant Character by Suppressing G2–M Transition Genes
14. Supplementary Figure 4 from Overexpression of the Transcription Factor MEF2D in Hepatocellular Carcinoma Sustains Malignant Character by Suppressing G2–M Transition Genes
15. Data from Overexpression of the Transcription Factor MEF2D in Hepatocellular Carcinoma Sustains Malignant Character by Suppressing G2–M Transition Genes
16. Supplementary Figure 2 from Overexpression of the Transcription Factor MEF2D in Hepatocellular Carcinoma Sustains Malignant Character by Suppressing G2–M Transition Genes
17. Supplementary Methods, Figure Legend, Tables 1 - 5 from Overexpression of the Transcription Factor MEF2D in Hepatocellular Carcinoma Sustains Malignant Character by Suppressing G2–M Transition Genes
18. Supplementary Figure 1 from Overexpression of the Transcription Factor MEF2D in Hepatocellular Carcinoma Sustains Malignant Character by Suppressing G2–M Transition Genes
19. FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy
20. Face off: a metabolic enzyme becomes a protein phosphatase
21. E3 ubiquitin ligases in cancer and implications for therapies
22. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways
23. CNNArginineMe: A CNN structure for training models for predicting arginine methylation sites based on the One-Hot encoding of peptide sequence
24. Recent Advances of Degradation Technologies Based on PROTAC Mechanism
25. Myocyte enhancer factor 2D promotes hepatocellular carcinoma through AMOTL2/YAP signaling that inhibited by luteolin
26. MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy
27. p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ
28. Cnnarginineme : A Cnn Structure for Training Models of Predicting Arginine Methylation Sites Based on the One-Hot Encoding of Peptide Sequence
29. Governing glutaminolysis by regulation of glutaminase succinylation
30. Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance
31. Fructose and fructose kinase in cancer and other pathologies
32. Eugenol protects cells against oxidative stress via Nrf2
33. Role of long non‐coding RNA in drug resistance in non‐small cell lung cancer
34. A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies
35. Light-induced control of protein destruction by opto-PROTAC
36. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity
37. ACTG1 and TLR3 are biomarkers for alcohol‑associated hepatocellular carcinoma
38. Ubiquitin-like proteins and their Chinese nomenclatures
39. A novel Camptothecin analogue inhibits colon cancer development and downregulates the expression of miR-155 in vivo and in vitro
40. Identification of new biomarkers for cisplatin-resistance in A549 human lung adenocarcinoma cells by an integrated bioinformatical analysis
41. Targeting microRNAs: a new action mechanism of natural compounds
42. ACTG1 and TLR3 are biomarkers for alcohol-associated hepatocellular carcinoma.
43. ERK inhibition sensitizes cancer cells to oleanolic acid-induced apoptosis through ERK/Nrf2/ROS pathway
44. Oleanolic acid inhibits proliferation and invasiveness of Kras-transformed cells via autophagy
45. Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway
46. ERK inhibition sensitizes cancer cells to oleanolic acid-induced apoptosis through ERK/Nrf2/ROS pathway.
47. Trop2-targeted therapies in solid tumors: advances and future directions.
48. Base editing of the mutated TERT promoter inhibits liver tumor growth.
49. Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion.
50. Myocyte enhancer factor 2D promotes hepatocellular carcinoma through AMOTL2/YAP signaling that inhibited by luteolin.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.